Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder

Inclusion Criteria: * Male subjects between the ages of 18 and 35, both inclusive, with a confirmed diagnosis of autism spectrum disorder (ASD) diagnosis. * Subjects must be in good general health, as determined by the investigator. * Subject's pre-study physical examination, vital signs and electrocardiogram (ECG) must not show any clinically significant abnormalities as determined by the investigator. * Subjects must be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and to understand the oral and written patient information * Provision of a signed, written informed consent. Exclusion Criteria: * Subjects showing major septal deviation or a significantly altered nasal epithelium. * Subjects with evidence of previous nasal disease, surgery, and dependence on inhaled drugs. * Subjects with current significant nasal congestion due to common colds. * Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, pulmonary, haematological or metabolic disorder. * Psychiatric co-morbidity that requires intervention (e.g., psychosis spectrum disorders, suicide intent) * Systemic illness requiring treatment within 2 weeks prior to Study Day 1. * History of significant drug or alcohol abuse (as per WHO Alcohol use disorder identification test and drug use disorder identification test criteria) Subjects with a positive screen for alcohol or drugs of abuse at screening/admission will be excluded from participation in the study. * Abnormal laboratory values which is deemed clinically significant by investigator. * Full scale IQ \< 75 (due to the prerequisite ability to complete self report measures). * Known allergic reactions or hypersensitivity to any component of the study medication in the nasal spray, such as propyl parahydroxybenzoate (E216), methyl parahydroxybenzoate (E218) and chlorobutanol hemihydrate. * Participation in any (other) clinical trial with an investigational medicinal product or medical device within 3 months prior to randomisation. * Other unspecified reasons that, in the opinion of the investigator or the sponsor make the subject unsuitable for enrollment.